- Home
- ATNM vs GROW Comparison
ATNM vs GROW Comparison
Compare ATNM & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATNM | GROW |
|---|---|---|
| Founded | 2000 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7M | 32.7M |
| IPO Year | 2013 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ATNM | GROW |
|---|---|---|
| Price | $0.98 | $3.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 136.3K | 31.8K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | ★ 14.17 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $90,000.00 | ★ $23,850,609.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.67 |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $0.94 | $2.23 |
| 52 Week High | $1.89 | $3.65 |
Technical Indicators
Market Signals| Indicator | ATNM | GROW |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 66.34 |
| Support Level | $0.97 | $3.10 |
| Resistance Level | $1.11 | $3.37 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 24.12 | 60.98 |
Price Performance
Historical ComparisonAbout ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.